›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:AVENIO ctDNA Targeted Kit
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
RocheType:
Research Use Only
Related tests:
1d
Insights into ctDNA assessment to detect minimal residual disease (MRD) in localized colorectal cancer. (PubMed, Sci Rep)
Important limitations, mainly sensitivity values need to be addressed. Further analyses are needed in order to position this technique in the routine clinical practice.
Journal • Minimal residual disease • Circulating tumor DNA
|
AVENIO ctDNA Targeted Kit • Oncomine™ Comprehensive Assay Plus
over1year
MUTATIONAL ANALYSIS OF CIRCULATING TUMOUR DNA (CTDNA) IN HIGH GRADE SEROUS OVARIAN CANCER (HGSC) USING CANCER PERSONALISED PROFILING BY DEEP SEQUENCING (CAPP-SEQ) (IGCS 2024)
80% of patients had detectable ctDNA at baseline (mutant DNA copies/ml) with somatic mutations found in TP53, BRCA1, KRAS, NRAS, MET and ERBB2 genes. CNVs were found in EGFR and MET. 69% of all plasmas were ctDNA+.
Tumor mutational burden • BRCA Biomarker • Circulating tumor DNA
|
EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BRCA1 (Breast cancer 1, early onset)
|
TP53 mutation • KRAS mutation • BRCA1 mutation • NRAS mutation • MET mutation
|
AVENIO ctDNA Targeted Kit
over2years
OSIRIS: Osimertinib Resistance in Patients With Non-small-cell Lung Carcinoma That Have Progressed. (clinicaltrials.gov)
P=N/A; Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date
|
EGFR (Epidermal growth factor receptor)
|
EGFR mutation
|
AVENIO ctDNA Targeted Kit
|
Tagrisso (osimertinib)
Share
